Treatment for Relapsed/Refractory Multiple Myeloma Shows Promising Clinical Activity, Safety
Teclistamab showed promising clinical activity and a tolerable safety profile in patients with relapsed/refractory multiple myeloma.
Teclistamab (formally JNJ-64007957) demonstrated encouraging clinical activity, along with a tolerable safety profile, in patients with relapsed/refractory multiple myeloma, according to results from an ongoing phase 1 study (NCT03145181).1 Results showed that at the recommended phase 2 dose (RP2D), the objective response rate (ORR) with teclistamab was 73% and the very good partial response rate (VGPR) or better was 55%; the complete response (CR) rate or better was 23%.
The agent was also found to be well tolerated at the RP2D, which was 1500 μg/kg given subcutaneously (SC); the maximum-tolerated dose (MTD) was not identified, and all reports of cytokine release syndrome (CRS) were of grades 1/2 and were generally confined to step-up doses and the first full doses of treatment.
“Teclistamab is an off-the-shelf therapy targeting BCMA, [and it] showed promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma,” said lead study author Alfred L. Garfall, MD, an assistant professor of medicine at the Hospital of the University of Pennsylvania, in a virtual presentation of the data.
There continues to be an unmet need for patients with relapsed/refractory multiple myeloma, he explained; for those who progress on available therapies, the ORR is approximately 30%, the median progression-free survival is an estimated to be 3 months, and the median overall survival ranges from 6 to 11 months.
